Comparison of risk-scoring systems in predicting symptomatic intracerebral hemorrhage after intravenous thrombolysis

Stroke

Volumn 44, Issue 6, 2013, Pages 1561-1566

  Sung, Sheng Feng ^a,c   Chen, Solomon Chih Cheng ^b   Lin, Huey Juan ^d,e   Chen, Yu Wei ^f,g   Tseng, Mei Chiun ^f   Chen, Chih Hung ^h  

^a Division of Neurology   (Taiwan)

^b Ditmanson Medical Foundation Chia Yi Christian Hospital   (Taiwan)

^c MIN HWEI COLLEGE OF HEALTH CARE MANAGEMENT   (Taiwan)

^d CHI MEI MEDICAL CENTER   (Taiwan)

^e CHIA NAN UNIVERSITY OF PHARMACY AND SCIENCE   (Taiwan)

^f Landseed Hospital   (Taiwan)

^g NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^h NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

AIS; Intracerebral hemorrhage; Intravenous thrombolysis; Prognosis; Risk score

Indexed keywords

AGED; ARTICLE; BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; CLINICAL EFFECTIVENESS; FEMALE; HEMORRHAGE AFTER THROMBOLYSIS SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; SAFE IMPLEMENTATION OF THROMBOLYSIS IN STROKE SYMPTOMATIC INTRACEREBRAL HEMORRHAGE RISK SCORE; SCORING SYSTEM; STATISTICAL ANALYSIS; SYMPTOMATIC INTRACEREBRAL HEMORRHAGE; TAIWAN;

AIS; INTRACEREBRAL HEMORRHAGE; INTRAVENOUS THROMBOLYSIS; PROGNOSIS; RISK SCORE;

AGED; CEREBRAL HEMORRHAGE; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; INJECTIONS, INTRAVENOUS; LOGISTIC MODELS; MALE; MIDDLE AGED; MODELS, STATISTICAL; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; STROKE; TAIWAN; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR;

EID: 84880154324     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.111.000651     Document Type: Article

References (30)

1. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581-1587.
2. Whiteley WN, Slot KB, Fernandes P, Sandercock P, Wardlaw J. Risk factors for intracranial hemorrhage in acute ischemic stroke patients treated with recombinant tissue plasminogen activator: a systematic review and meta-analysis of 55 studies. Stroke. 2012;43:2904-2909.
3. Strbian D, Sairanen T, Meretoja A, Pitkäniemi J, Putaala J, Salonen O, et al.; Helsinki Stroke Thrombolysis Registry Group. Patient outcomes from symptomatic intracerebral hemorrhage after stroke thrombolysis. Neurology. 2011;77:341-348.
4. Brown DL, Barsan WG, Lisabeth LD, Gallery ME, Morgenstern LB. Survey of emergency physicians about recombinant tissue plasminogen activator for acute ischemic stroke. Ann Emerg Med. 2005;46:56-60.
5. Cucchiara B, Tanne D, Levine SR, Demchuk AM, Kasner S. A risk score to predict intracranial hemorrhage after recombinant tissue plas-minogen activator for acute ischemic stroke. J Stroke.Cerebrovasc Dis. 2008;17:331-333.
6. Lou M, Safdar A, Mehdiratta M, Kumar S, Schlaug G, Caplan L, et al. The HAT Score: a simple grading scale for predicting hemorrhage after thrombolysis. Neurology. 2008;71:1417-1423.
7. Saposnik G, Fang J, Kapral MK, Tu JV, Mamdani M, Austin P, et al.; Investigators of the Registry of the Canadian Stroke Network (RCSN); Stroke Outcomes Research Canada (SORCan) Working Group. The iScore predicts effectiveness of thrombolytic therapy for acute ischemic stroke. Stroke. 2012;43:1315-1322.
8. Mazya M, Egido JA, Ford GA, Lees KR, Mikulik R, Toni D, et al.; SITS Investigators. Predicting the risk of symptomatic intracerebral hemorrhage in ischemic stroke treated with intravenous alteplase: Safe Implementation of Treatments in Stroke (SITS) symptomatic intracere-bral hemorrhage risk score. Stroke. 2012;43:1524-1531.
9. Strbian D, Engelter S, Michel P, Meretoja A, Sekoranja L, Ahlhelm FJ, et al. Symptomatic intracranial hemorrhage after stroke thrombolysis: the SEDAN score. Ann Neurol. 2012;71:634-641.
10. Menon BK, Saver JL, Prabhakaran S, Reeves M, Liang L, Olson DM, et al. Risk score for intracranial hemorrhage in patients with acute isch-emic stroke treated with intravenous tissue-type plasminogen activator. Stroke. 2012;43:2293-2299.
11. Saposnik G, Guzik AK, Reeves M, Ovbiagele B, Johnston SC. Stroke Prognostication using Age and NIH Stroke Scale: SPAN-100. Neurology. 2013;80:21-28.
12. Bleeker SE, Moll HA, Steyerberg EW, Donders AR, Derksen-Lubsen G, Grobbee DE, et al. External validation is necessary in prediction research: a clinical example. J Clin Epidemiol. 2003;56:826-832.
13. Hsieh FI, Lien LM, Chen ST, Bai CH, Sun MC, Tseng HP, et al.; Taiwan Stroke Registry Investigators. Get With the Guidelines-Stroke performance indicators: surveillance of stroke care in the Taiwan Stroke Registry: Get With the Guidelines-Stroke in Taiwan. Circulation. 2010;122:1116-1123.
14. Sung SF, Tseng MC. Code stroke: A mismatch between number of activation and number of thrombolysis. J Formos Med Assoc. September 10, 2012. doi:10.1016/j.jfma.2012.07.029.
15. Cronin CA, Shah N, Morovati T, Hermann LD, Sheth KN. No increased risk of symptomatic intracerebral hemorrhage after thrombolysis in patients with European Cooperative Acute Stroke Study (ECASS) exclusion criteria. Stroke. 2012;43:1684-1686.
16. Adams H P, del Zoppo G, Alberts MJ, Bhatt DL, Brass L, Furlan A, et al. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: the American Academy of Neurology affrms the value of this guideline as an educational tool for neurologists. Stroke. 2007;38:1655-1711.
17. Taiwan Guidelines for the Management of Stroke 2008. Taiwan Stroke Society web site. http://www.stroke.org.tw/guideline/guideline-new.asp. Accessed February 4, 2013.
18. Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, et al. Randomised double-blind placebo-controlled trial of throm-bolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet. 1998;352:1245-1251.
19. Wahlgren N, Ahmed N, Dávalos A, Ford GA, Grond M, Hacke W, et al.; SITS-MOST investigators. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet. 2007;369:275-282.
20. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44:837-845.
21. Chao AC, Hsu HY, Chung CP, Liu CH, Chen CH, Teng MM, et al.; Taiwan Thrombolytic Therapy for Acute Ischemic Stroke (TTT-AIS) Study Group. Outcomes of thrombolytic therapy for acute ischemic stroke in Chinese patients: the Taiwan Thrombolytic Therapy for Acute Ischemic Stroke (TTT-AIS) study. Stroke. 2010;41:885-890.
22. LaValley MP. Logistic regression. Circulation. 2008;117:2395-2399.
23. Seet RC, Rabinstein AA. Symptomatic intracranial hemorrhage following intravenous thrombolysis for acute ischemic stroke: a critical review of case defnitions. Cerebrovasc Dis. 2012;34:106-114.
24. Dzialowski I, Hill MD, Coutts SB, Demchuk AM, Kent DM, Wunderlich O, et al. Extent of early ischemic changes on computed tomography (CT) before thrombolysis: prognostic value of the Alberta Stroke Program Early CT Score in ECASS II. Stroke. 2006;37:973-978.
25. Wardlaw JM, Dorman PJ, Lewis SC, Sandercock PA. Can stroke physicians and neuroradiologists identify signs of early cerebral infarction on CT? J Neurol Neurosurg Psychiatry. 1999;67:651-653.
26. Guzik AK, Raman R, Ernstrom K, Meyer DM, Sodhi A, Ovbiagele B, et al. Clinical Outcomes of the "Stroke100 Club." Stroke. 2012;43:A3572.
27. Rha JH, Shrivastava VP, Wang Y, Lee KE, Ahmed N, Bluhmki E, et al. Thrombolysis for acute ischaemic stroke with alteplase in an Asian population: results of the multicenter, multinational Safe Implementation of Thrombolysis in Stroke-Non-European Union World (SITS-NEW). Int J Stroke. September 18, 2010 [Epub ahead of print].
28. Gumbinger C, Gruschka P, Böttinger M, Heerlein K, Barrows R, Hacke W, et al. Improved prediction of poor outcome after thromboly-sis using conservative defnitions of symptomatic hemorrhage. Stroke. 2012;43:240-242.
29. Sharma VK, Ng KW, Venketasubramanian N, Saqqur M, Teoh HL, Kaul S, et al. Current status of intravenous thrombolysis for acute ischemic stroke in Asia. Int J Stroke. 2011;6:523-530.
30. Chen CH, Hsieh C Y, Lai TB, Chuang MT, Chen WL, Sun MC. Optimal dose for stroke thrombolysis in Asians: low dose may have similar safety and effcacy as standard dose. J Thromb Haemost. 2012;10:1270-1275.